Abstract
Objective: Assess the utilization of “migraine cocktail” in acute headache management at a tertiary level emergency department (ED)
Background: Migraine headache is a frequent ED admission. Patients receive “migraine cocktail”, a combination therapy that varies with institutions. Common constituents include Dopamine antagonist, NSAID and antihistamine. There is insufficient evidence about the headache relief and the reduced ED stay by using the combination of drugs.
Design/Methods: We did retrospective chart review of patients seeking acute headache treatment in ED from July 2017–2019. Inclusion criteria was acute primary headache patients from age 5–18 years. Patients with secondary causes of headache were excluded. Primary outcome was reduction in headache pain score within 4 hours of treatment. Secondary outcome measures included length of ED stay, hospital admission rate, and ED readmission within 48 hours.
Results: Study yielded 247 patients, among which 47 met inclusion criteria. Out of 47 patients, 60% had a diagnosis of migraine. Mean age was 12.7 years (SD 3), and 70% were female. Mean ED length of stay was 4.6 hours (SD 1.97, p<0.05). Nineteen percent of patients were hospitalized. Most commonly used combination treatment was Benadryl, Metoclopramide and Ketorolac (23%). Metoclopramide was substituted with Prochlorperazine based on physician preference. Fluid bolus was given to 74% of patients, among which 77% were discharged home from ED. Mean pre-treatment pain score was 7.6 (SD 1.6) and post-treatment pain score was 3 (SD 2.4). Mean difference between the two scores was 4.5 (CI, 3.9–5.2), p<0.05. Pain score improvement is associated with ED discharge (Odds ratio 0.25). Age, gender, type of cocktail class, headache duration before ED visit did not affect the discharge from ED
Conclusions: Two third patients were discharged with diagnosis of migraine. Migraine cocktail helped in reducing pain score and hospital admission rates.
Disclosure: Dr. Ghosh has nothing to disclose. Dr. Lapus has nothing to disclose. Dr. Flemmons has nothing to disclose. Dr. Koenig has nothing to disclose. Dr. Gourishankar has nothing to disclose.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg